<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01488214</url>
  </required_header>
  <id_info>
    <org_study_id>2009_10</org_study_id>
    <secondary_id>PHRC 2009/API</secondary_id>
    <secondary_id>2009-A01313-54</secondary_id>
    <nct_id>NCT01488214</nct_id>
  </id_info>
  <brief_title>Neuropsychiatric Scleroderma Study: Systematic Evaluation of Neuropsychiatric Involvement in Systemic Sclerosis</brief_title>
  <acronym>NeuroScS</acronym>
  <official_title>Assessment of Neuropsychiatric Involvement in Systemic Sclerosis.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Lille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Lille</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Systemic sclerosis is a rare disease with vascular involvement and systemic fibrosis. This
      disease is usually thought to spare central nervous system. However, neuropsychiatric
      manifestations like depression and cognitive functions impairment seem to be frequent.
      Pathophysiology of this neuropsychiatric manifestations is currently unknown. White matter
      hyperintensities have been reported suggested CNS vascular manifestations in systemic
      sclerosis. Whether this CNS vascular involvement plays a role in neuropsychiatric
      manifestations in systemic sclerosis is unknown. The primary objective of this prospective
      and multicentre study is to assess a link between neuropsychiatric manifestations and CNS
      involvement in systemic sclerosis. Secondary objectives are to assess the frequency of
      neuropsychiatric manifestations, to compare central nervous system abnormality between
      scleroderma patient and healthy subjects. Central nervous system involvement and
      neuropsychiatric manifestations will be systematically assessed through central nervous
      system imaging and questionnaires.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 16, 2011</start_date>
  <completion_date type="Actual">October 24, 2017</completion_date>
  <primary_completion_date type="Actual">October 24, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Odds-ratio between neuropsychiatric manifestations and magnetic resonance imaging abnormalities</measure>
    <time_frame>5 weeks</time_frame>
    <description>Odds-ratio between neuropsychiatric manifestations and magnetic resonance imaging abnormalities</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">108</enrollment>
  <condition>Systemic Sclerosis</condition>
  <arm_group>
    <arm_group_label>Scleroderma patient</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Evaluation of Scleroderma patient</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy subjects</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Evaluation of healthy subjects</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Magnetic resonance Imaging</intervention_name>
    <description>Magnetic resonance Imaging Assessment</description>
    <arm_group_label>Scleroderma patient</arm_group_label>
    <arm_group_label>Healthy subjects</arm_group_label>
    <other_name>Cognitive, psychiatric and neurological evaluation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female between 18 and 65 yo

          -  With scleroderma (American College of Rheumatology and/or Leroy et Medsger)

          -  Informed consent given

        Exclusion Criteria:

          -  Other auto-immune disease

          -  non french native speakers

          -  severe arterial hypertension

          -  diabetes

          -  anemia

          -  renal insufficiency

          -  cranial trauma

          -  history of neurological disorder or neurotoxic treatment

          -  pregnancy or breast feeding

          -  impossibility or non compliance to perform the protocol flow chart

          -  contra indications to MRI
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Launay, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Lille University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Amar Smail, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Amiens University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Boris Bienvenu, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Caen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Isabelle Marie, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rouen University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Caen University Hospital</name>
      <address>
        <city>Caen</city>
        <state>Calvados</state>
        <zip>14000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lille University hosiptal</name>
      <address>
        <city>Lille</city>
        <state>Nord</state>
        <zip>59000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rouen University hospital</name>
      <address>
        <city>Rouen</city>
        <state>Seine-Maritime</state>
        <zip>76 000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Amiens Launay</name>
      <address>
        <city>Amiens</city>
        <state>Sommes</state>
        <zip>80 000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/16960939</url>
  </link>
  <results_reference>
    <citation>Launay D, Remy-Jardin M, Michon-Pasturel U, Mastora I, Hachulla E, Lambert M, Delannoy V, Queyrel V, Duhamel A, Matran R, De Groote P, Hatron PY. High resolution computed tomography in fibrosing alveolitis associated with systemic sclerosis. J Rheumatol. 2006 Sep;33(9):1789-801.</citation>
    <PMID>16960939</PMID>
  </results_reference>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 25, 2011</study_first_submitted>
  <study_first_submitted_qc>December 7, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 8, 2011</study_first_posted>
  <last_update_submitted>November 8, 2017</last_update_submitted>
  <last_update_submitted_qc>November 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Systemic Sclerosis</keyword>
  <keyword>neuropsychiatric manifestations</keyword>
  <keyword>magnetic resonance imaging</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Scleroderma, Systemic</mesh_term>
    <mesh_term>Scleroderma, Diffuse</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

